Silvia Sabbioni

Simian virus 40 infection in humans and association with human diseases: results and hypotheses.

Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood.

Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.

MicroRNA gene expression deregulation in human breast cancer.

BK virus, JC virus and Simian Virus 40 infection in humans, and association with human tumors.

Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer.

MicroRNAs in human cancer: from research to therapy.

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Simian virus 40 in humans.

Open letter to Senator Rita Levi-Montalcini.

MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation.

MicroRNA involvement in hepatocellular carcinoma.

MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.

MicroRNA response to environmental mutagens in liver.

microRNA involvement in hepatocellular carcinoma.

MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer.

In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.

Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.

miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs.

Role of microRNAs in hepatocellular carcinoma: a clinical perspective.

Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.

microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.

Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR.

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.